ACA
AVEO

Avoro Capital Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Avoro Capital Advisors’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-323,189
Closed -$9.37M – 63
2018
Q1 		$9.37M Sell
323,189
-77,500
-19% -$2.27M 0.45% 31
2017
Q4 		$11.2M Sell
400,689
-79,936
-17% -$2.48M 0.72% 26
2017
Q3 		$17.5M Sell
480,625
-182,620
-28% -$5.65M 1.36% 22
2017
Q2 		$14.7M Buy
663,245
+269,442
+68% +$2.12M 1.86% 15
2017
Q1 		$2.32M Buy
+393,803
New +$2.84M 0.3% 36

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Avoro Capital Advisors's AVEO Position: Q2 2018 in Review

Avoro Capital Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2018, closing a stake of 323,189 shares — an estimated $9.37M sold.

Avoro Capital Advisors first reported a position in AVEO in Q1 2017 and held it in 5 quarters. The position peaked at $17.5M in Q3 2017. 94 funds tracked by Wall St. Rank hold AVEO as of Q2 2018.

  • Avoro Capital Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Avoro Capital Advisors sold 323,189 AVEO Pharmaceuticals, Inc. shares in Q2 2018, an estimated $9.37M.
  • Avoro Capital Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2017 and held it in 5 quarters.
  • Avoro Capital Advisors's AVEO Pharmaceuticals, Inc. position peaked at $17.5M in Q3 2017.
  • 94 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2018.

Based on Avoro Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.